Liav Abraham analyst CITI

Currently out of the existing stock ratings of Liav Abraham, 18 are a HOLD (21.95%), 62 are a BUY (75.61%), 2 are a SELL (2.44%).

Liav Abraham

Work Performance Price Targets & Ratings Chart

Analyst Liav Abraham, currently employed at CITI, has had 63.12% of price targets met with an average potential upside of 20.21%, reached in 655 days on average.

Liav Abraham has documented 163 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TEVA, Teva Pharma Industries Ltd ADR at 30-Apr-2021.

Wall Street Analyst Liav Abraham

Analyst best performing recommendations are on ELAN (ELANCO ANIMAL HEALTH).
The best stock recommendation documented was for TEVA (TEVA PHARMA INDUSTRIES LTD ADR) on 5/1/2018. The price target of $24 was fulfilled within 42 days with a profit of $5.29 (28.27%), with a performance score of 6.73.

Average potential price target upside

AGN Allergan plc ALKS Alkermes Plc ELAN Elanco Animal Health ENDP Endo International PLC HZNP Horizon Pharma PLC SGYP Synergy Pharmaceuticals TEVA Teva Pharma Industries Ltd ADR ZTS Zoetis JAZZ Jazz Pharmaceuticals PLC MYL Viatris VTRS Viatris DBVT DBV Technologies

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 21-Dec-2016

$193

$202

6 years 7 months 1 days ago
(21-Apr-2020)

4/12 (33.33%)

$8.96 (4.87%)

141

Hold Since 08-May-2019

$203

$178

6 years 9 months 12 days ago
(10-Feb-2020)

5/19 (26.32%)

$4.87 (2.46%)

74

Buy Since 03-Aug-2017

$198

$184

6 years 10 months ago
(22-Jan-2020)

5/14 (35.71%)

$7.8 (4.10%)

134

Buy Since 03-Aug-2015

$200

7 years 3 days ago
(19-Nov-2019)

2/12 (16.67%)

$73.92 (58.63%)

290

Hold Since 19-Nov-2019

$203

$189

7 years 3 days ago
(19-Nov-2019)

1/2 (50%)

$19.19 (10.44%)

96

Show more analysts

Stocks Liav Abraham covered previously. Scores are shown for active stocks only.

INSM Insmed

Please expand the browser size to see the chart

What Year was the first public recommendation made by Liav Abraham?

On 2012
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?